As of November 7, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Cocrystal Pharma, Inc. The largest reported stake is Opko Health, Inc.'s, at 29.6%. 5 filings are on record since October 2, 2025 (Schedule 13D/A, November 6, 2026).
Sell to companies like Cocrystal Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Opko Health, Inc. · Sole voting: 5,692,916 · Shared voting: 0 · Sole dispositive: 5,692,916 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-11-06
- · Reporting person: Phillip Frost, M.D. · Sole voting: 2,013,876 · Shared voting: 0 · Sole dispositive: 2,013,876 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-07
- · Holder: Opko Health, Inc. · Percent: 29.6% · SCHEDULE 13D
- · Holder: Phillip Frost, M.D. · Percent: 17.8% · SCHEDULE 13D/A
- · Holder: Phillip Frost, M.D. · Percent: 10.6% · SCHEDULE 13D/A
Cocrystal Pharma, Inc. has 5 Schedule 13D or 13G filings on record since 2025-10-02. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Opko Health, Inc. | 29.6% | 5,692,916 | SCHEDULE 13D/A, 2026-11-06 | 2026-11-04 |
| Phillip Frost, M.D. | 13.9% | 2,784,719 | SCHEDULE 13D/A, 2026-08-07 | 2026-08-03 |
Holding shares or following this stake? See who's behind Cocrystal Pharma, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Cocrystal Pharma, Inc. and the records around it.
Cocrystal Pharma, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Phillip Frost, M.D. also filed stake reports on 3 other companies: Safe Pro Group Inc. (Sep 2026), Fluent, Inc. (Jan 2026)
Watch Cocrystal Pharma, Inc.
Get an email when Cocrystal Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cocrystal Pharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cocrystal Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cocrystal Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Opko Health, Inc. | 5,692,916 | 0 | 5,692,916 | 0 | SCHEDULE 13D/A, 2026-11-06 |
| Frost Phillip Md Et Al | 2,788,106 | 0 | 2,788,106 | 0 | SCHEDULE 13D/A, 2026-11-06 |
| Frost Gamma Investments Trust | 2,712,977 | 0 | 2,712,977 | 0 | SCHEDULE 13D/A, 2026-11-06 |
| Rubin Steven D | 75,872 | 0 | 75,872 | 0 | SCHEDULE 13D/A, 2026-11-06 |
| Phillip Frost, M.D. | 2,013,876 | 0 | 2,013,876 | 0 | SCHEDULE 13D/A, 2026-08-07 |
| Frost Gamma Investments Trust | 1,993,551 | 0 | 1,993,551 | 0 | SCHEDULE 13D/A, 2026-08-07 |
The latest filing identifies Cocrystal Pharma, Inc. by CUSIP 19188J409 and gives its principal executive office as 19805 N. CREEK PARKWAY, BOTHELL, WA 98011 (SCHEDULE 13D/A, 2026-11-06).
Source of funds (Item 3)
On August 3, 2026, the Reporting Persons purchased 75,000 shares of the Issuer's common stock in the open market at $0.9412 per share. On August 5, 2026, the Reporting Persons purchased an additional 10,000 shares of the Issuer's common stock in the open market at $0.9816 per share.Phillip Frost, M.D., SCHEDULE 13D/A, 2026-08-07
Purpose of Transaction (Item 4)
Phillip Frost, M.D.
The Reporting Persons acquired the shares of common stock for investment purposes. These securities are held by Frost Gamma Investments Trust, of which Phillip Frost, MD is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.Item 4 of the SCHEDULE 13D/A filed 2026-08-07
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-02 | Phillip Frost, M.D. | 10.6% | SCHEDULE 13D/A |
| 2025-10-30 | Phillip Frost, M.D. | 17.8% | SCHEDULE 13D/A |
| 2026-08-07 | Opko Health, Inc. | 29.6% | SCHEDULE 13D |
| 2026-08-07 | Phillip Frost, M.D. | 13.9% | SCHEDULE 13D/A |
| 2026-11-06 | Opko Health, Inc. | 29.6% | SCHEDULE 13D/A |
Questions about who owns Cocrystal Pharma, Inc.
Who owns Cocrystal Pharma, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Cocrystal Pharma, Inc.: Opko Health, Inc. (29.6%, Schedule 13D/A, filed 2026-11-06) and Phillip Frost, M.D. (13.9%, Schedule 13D/A, filed 2026-08-07).
Who are the largest shareholders of Cocrystal Pharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Cocrystal Pharma, Inc. on this page are Opko Health, Inc. (29.6%) and Phillip Frost, M.D. (13.9%).
When did Opko Health, Inc. buy into Cocrystal Pharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Opko Health, Inc. on this page is the Schedule 13D, filed 2026-08-07, reporting 29.6%; its latest, Schedule 13D/A filed 2026-11-06, reports 29.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Cocrystal Pharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 18, 2026 | Leadership change: Carol L. Brosgart appointed, Director | — | Leadership changes | Source |
| June 9, 2026 | Leadership change: James Sapirstein appointed, Chief Executive Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Cocrystal Pharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.